Hope or hype? Clinicians' dilemma in the era of ever-expanding antigens in membranous nephropathy.

The article discusses the challenges faced by clinicians in diagnosing and treating membranous nephropathy (MN), a leading cause of nephrotic syndrome. The discovery of multiple antigens associated with MN has expanded our understanding of the disease and its various subtypes. The article explores the implications of these discoveries for clinical practice, including the potential for targeted therapies such as chimeric antigen receptor T cell (CAR-T) therapy. However, the article also acknowledges the limitations and complexities of implementing these advancements in patient care. The authors suggest that specialized centers with expertise in MN may be beneficial for managing complex cases. [Extracted from the article]